Maralixibat Chloride

- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia. Cholestatic liver diseases are characterized by impaired bile flow, resulting in elevated serum bile acids, severe pruritus, and significantly reduced quality of life. While LIVMARLI is approved in the United States and European Union for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), patients with other rare cholestatic liver diseases continue to experience debilitating itch and treatment options remain limited. “Completing enrollment in EXPAND marks an important milestone in our efforts to broaden the reach of LIVMARLI to additional patients living with cholestatic pruritus,” said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. “Itch due to cholestasis profoundly affects the daily lives of patients and their families. We aim to address the unmet medical needs of these patients by leveraging our established IBAT mechanism.” The EXPAND study enrolled patients with cholestatic pruritus associated with a range of rare cholestatic liver diseases. In the 20-week placebo-controlled portion, patients are randomized to receive maralixibat 285 micrograms per kilogram (µg/kg) twice daily or placebo. The primary endpoint is change in pruritus severity from baseline to Week 20. Secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. “For the patients and families living with rare liver diseases, cholestatic pruritus isn’t just an itch—it can be relentless, exhausting, and life-altering,” said Dr. Mercedes Martinez, M.D., Professor of Pediatrics and Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons. “Yet for many of these conditions, there are still no approved treatment options for pruritus. The EXPAND study marks an important milestone in exploring whether a targeted therapy like LIVMARLI can offer meaningful relief to patients who urgently need better treatment options.” “Families affected by biliary atresia and other rare cholestatic conditions understand the relentless burden of itch,” said Jen Lau, MPH, Co-Founder and Executive Director of BARE, Inc. (Biliary Atresia Research and Education). “The completion of enrollment in EXPAND brings hope that more patients may soon have access to a much-needed treatment option.” Topline data from the EXPAND study are expected in the fourth quarter of 2026. About the EXPAND Phase 3 Study EXPAND is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LIVMARLI ® (maralixibat) in children aged 6 months and older and adults with cholestatic pruritus associated with rare cholestatic liver diseases. These diseases include biliary atresia and other rare conditions for which LIVMARLI is not currently approved. The primary endpoint is change in pruritus severity from baseline to Week 20. Secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. About LIVMARLI ® (maralixibat) oral solution and LIVMARLI ® (maralixibat) tablets LIVMARLI® (maralixibat) is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com . LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for the treatment of ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website. IMPORTANT SAFETY INFORMATION Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein. LIVMARLI can cause side effects, including: Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal. Stomach and intestinal (gastrointestinal) problems . LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you. A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with ALGS and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects. US Prescribing Information EU SmPC Canadian Product Monograph About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI ® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM ® (cholic acid) for bile-acid synthesis disorders, and CTEXLI ® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at and follow Mirum on Facebook , LinkedIn , Instagram and X . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, LIVMARLI ® (maralixibat) efficacy in additional patients living with cholestatic pruritus, Mirum’s leadership in rare disease, expectations regarding LIVMARLI ® (maralixibat) ongoing development, including the potential completion of and successful results from the EXPAND trial, the anticipated timing for data from the EXPAND study, and any potential regulatory submission. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expected,” “will,” “could,” “would,” “potential,” “continue,” “plans,” “intended,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized; risk and uncertainties arising from the integration of an acquired company, its employees and its assets with Mirum’s business; risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized; risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies and the potential that estimated prevalences are materially inaccurate; the risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at . All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Contacts Investor Contact: Andrew McKibben ir@mirumpharma.com Media Contact: Meredith Kiernan Media@mirumpharma.com

GSK plc (LSE/NYSE: GSK), headquartered in London, and Bologna-based Alfasigma S.p.A. have entered into a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture, and commercialise linerixibat, an oral ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in patients with primary biliary cholangitis (PBC). Linerixibat is currently under approval review by the US FDA for cholestatic pruritus in primary biliary cholangitis (PBC), with a PDUFA target date of 24 March 2026, while filings have also been made in all major markets. GSK will receive an upfront payment of USD 300 million, with additional regulatory and sales-based milestones bringing the total potential value to approximately USD 690 million, excluding royalties. The financial structure includes a USD 100 million milestone tied to US FDA approval, which GSK expects prior to transaction closing based on a PDUFA target date of 24 March, 2026. A further USD 20 million is payable upon EU and UK approval, with up to USD 270 million in sales-based milestone payments. GSK will also receive tiered double-digit royalties on worldwide net sales. The transaction is subject to customary conditions. Linerixibat (GSK2330672) is a small molecule that selectively inhibits the ileal bile acid transporter (IBAT/SLC10A2) in the gut, reducing reabsorption of bile acids into the enterohepatic circulation. In PBC, impaired bile flow leads to accumulation of bile acids systemically, which is thought to drive cholestatic pruritus — a persistent internal itch that can cause sleep disturbance, fatigue, and reduced quality of life. By lowering circulating bile acid levels, linerixibat addresses a mechanistic link between bile acid excess and pruritus severity. Marketing applications are under regulatory review in the US, EU, UK, China, and Canada, based on data from the Phase III GLISTEN trial, which met its primary and key secondary endpoints. Linerixibat holds Orphan Drug Designation in the US, EU, and Japan, and priority review status in China. For GSK, the out-licensing represents a strategic narrowing of its hepatology portfolio toward chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-associated liver disease (ALD). For Alfasigma, the deal adds a late-stage PBC asset to a portfolio already anchored in hepatology following the company’s approximately USD 750 million acquisition of Intercept Pharmaceuticals in 2023, which brought obeticholic acid (Ocaliva), a farnesoid X receptor (FXR) agonist approved for primary biliary cholangitis treatment. The linerixibat PBC drug licence gives Alfasigma a second distinct mechanism in the same disease. The IBAT class has also seen major deal activity: Ipsen announced its acquisition of Albireo in January 2023 and completed it in March 2023 for around USD 952 million, and Gilead acquired CymaBay for USD 4.3 billion in March 2024. Other molecules targeting IBAT or cholestatic pruritus in PBC under active development include: Odevixibat (Ipsen; originally developed by Albireo) — an IBAT inhibitor approved for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome, with additional clinical studies evaluating its use in other cholestatic liver diseases. Maralixibat (Mirum Pharmaceuticals; originally developed by Shire/Takeda) — an IBAT inhibitor approved for Alagille syndrome and PFIC, with ongoing studies in additional pediatric cholestatic disorders. Volixibat (developed by Shire, now Mirum Pharmaceuticals) — an IBAT inhibitor being evaluated in clinical studies for cholestatic pruritus, including in patients with primary biliary cholangitis and primary sclerosing cholangitis. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website